Short Interest in Chromocell Therapeutics Co. (NYSE:CHRO) Drops By 28.1%

Chromocell Therapeutics Co. (NYSE:CHRO) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 125,900 shares, a drop of 28.1% from the May 15th total of 175,100 shares. Based on an average daily volume of 672,100 shares, the short-interest ratio is currently 0.2 days. Approximately 14.2% of the shares of the stock are short sold.

Chromocell Therapeutics Trading Up 2.3%

NYSE:CHRO opened at $1.25 on Wednesday. Chromocell Therapeutics has a 12-month low of $0.45 and a 12-month high of $3.80. The firm has a market cap of $8.23 million, a price-to-earnings ratio of -1.01 and a beta of 3.22. The company’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.34.

Chromocell Therapeutics Company Profile

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.